-+ 0.00%
-+ 0.00%
-+ 0.00%

argenx SE To Present New Data From Phase 3 Study Evaluating VYVGART Hytrulo In Patients With Autoimmune Myositis, Focused On IMNM And DM, At ACR Convergence 2026

Benzinga·10/19/2026 12:07:53
Listen to the news
  • Results from the global Phase 3 ALKIVIA study, the first registrational study investigating an FcRn blocker in autoimmune myositis, show efgartigimod provides clinically meaningful improvements in IMNM and DM
     
  • Patient improvements observed as early as Week 4 and sustained through 52 weeks
     
  • Late-breaking oral presentation on Wednesday, November 11th, 9:15 – 9:30 AM ET
     

October 19, 2026, 8:00 AM ET

Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), the immunology innovation company, today announced that new data from the Phase 3 study evaluating VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in patients with autoimmune myositis, focused on immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM), will be featured as a late-breaking oral presentation (#LB24) during the American College of Rheumatology (ACR) Convergence 2026 from November 6-11, 2026, in Orlando, Florida.